arrow
T

T. Okamura

anjo kosei hospital
H指数:17
被引数:1,361

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC

在转移性CRPC中,达到CRPC前达到的最低PSA水平可预测阿比特龙的治疗反应,但不能预测恩扎卢amide的治疗反应

2026-09-290
PRE
Prognostic impact of diabetes or hypertension in smokers with CRPC receiving enzalutamide or abiraterone

吸烟的转移性去势抵抗性前列腺癌患者接受恩扎卢替尼或阿比特龙治疗时,糖尿病或高血压的预后影响

2026-09-190
PRE
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa

恩扎卢替尼和阿比特龙在既往有其他癌症史的患者中的有效性和安全性:针对PCa的ENABLE研究的亚组分析

2026-05-201
PRE
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study

恩扎卢替尼和醋酸阿比特龙联合泼尼松龙在老年去势抵抗性前列腺癌患者中的有效性与安全性:来自ENABLE研究的亚组分析

2025-04-030
PRE
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
2022-07-0110
OAAI
Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guerin Instillation Therapy for Nonmuscle Invasive Bladder Cancer
2016-01-0148
PREAI